ASH Update on SCT for Myeloid and Lymphoid Leukemias: Apamistamab as Part of the Conditioning Regimen, Ruxolitinib for SR-aGVHD, Enasidenib as Post-Transplant Maintenance, Venetoclax Mono, Targeted T-Cell Maintenance

61 views
March 8, 2021
Comments 0
Login to view comments. Click here to Login